Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | Advances in device-aided therapies and subcutaneous infusions for Parkinson’s disease

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, discusses advances in device-aided therapies and infusion therapies for patients with advanced Parkinson’s disease. Prof. Antonini highlights advances in the delivery of levodopa to improve the quality of sleep and stabilise symptoms. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

We now have a number of procedures and devices that we can implement in people with Parkinson’s when they develop motor complications. Generally, we identify them by a very simple criteria, which is five hours of OFF time or five intakes of levodopa or two hours OFF time or one hour with dyskinesias. This 5-2-1 criteria, it has been used now broadly to identify people who may be suitable for advanced therapies...

We now have a number of procedures and devices that we can implement in people with Parkinson’s when they develop motor complications. Generally, we identify them by a very simple criteria, which is five hours of OFF time or five intakes of levodopa or two hours OFF time or one hour with dyskinesias. This 5-2-1 criteria, it has been used now broadly to identify people who may be suitable for advanced therapies. Infusion therapies have undergone an important development in recent years, as we have been able in the last two, three years to use subcutaneous levodopa delivery for 24 hours. I think the main advances that we have seen in this field regard the fact that we can provide the levodopa delivery throughout the night and that we can improve significantly the quality of sleep. People with Parkinson’s can wake up better and we can replace the total amount of oral levodopa by a subcutaneous infusion which lets people be more stable. It helps them reduce off time and extend the good mobility time throughout the day.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...